Is nano too big?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 1, 2014, Pages 4-6

  Mier, Walter ^a   Babich, John ^b   Haberkorn, Uwe ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; DOXORUBICIN; LIPOSOME; MACROGOL; MICROSPHERE; NANOMATERIAL; NANOPARTICLE; OPSONIN; PLASMA PROTEIN; RADIOISOTOPE; TRACER; YTTRIUM 90;

ARTIFICIAL EMBOLISM; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CIRCULATION TIME; DIFFUSION COEFFICIENT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; EDITORIAL; ENDOTHELIUM CELL; EXPERIMENTAL THERAPY; EXTRAVASATION; GENE THERAPY; HAND FOOT SYNDROME; HUMAN; HYPOXIA; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LYMPH VESSEL; MACROMOLECULE; MOLECULAR ELECTRONICS; MOLECULAR IMAGING; MOLECULAR MECHANICS; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MEDICINE; PARTICLE SIZE; POLYMERIZATION; RETICULOENDOTHELIAL SYSTEM; SENTINEL LYMPH NODE; TISSUE PRESSURE; VACCINATION;

DRUG DISCOVERY; HUMANS; MICROVESSELS; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE;

EID: 84890575991     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2574-9     Document Type: Editorial

References (11)

1. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging. 2005;32 Suppl 2:S384-403. doi: 10.1007/s00259-005-1928-3.
2. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 2010;116:1454-9. doi: 10.1182/blood-2009-12-258038.
3. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868-78. doi: 10.1002/hep.24451.
4. Lovrics PJ, Cornacchi SD, Vora R, Goldsmith CH, Kahnamoui K. Systematic review of radioguided surgery for non-palpable breast cancer. Eur J Surg Oncol. 2011;37:388-97. doi: 10.1016/j.ejso.2011.01.018.
5. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-9.
6. Hulsermann U, Hoffmann MM, Massing U, Fricker G. Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. J Drug Target. 2009;17:610-8. doi: 10.1080/10611860903105986.
7. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;(197):55-86. doi: 10.1007/978-3-642-00477-3-2
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
9. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-92. doi: 10.1038/nrc1893.
10. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-61. doi: 10.1158/0008-5472.CAN-06-2531.
11. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, et al. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem. 2005;16:237-40. doi: 10.1021/bc034216c.